Sanofi Management Discusses Q2 2012 Results - Earnings Call Transcript

Sanofi (SNY)

Q2 2012 Earnings Call

July 26, 2012 8:30 am ET

Executives

Sébastien Martel

Christopher A. Viehbacher - Chief Executive Officer, Director and Member of Strategy Committee

Hanspeter Spek - President of Global Operations

Olivier Charmeil - Senior Vice President of Sanofi Pasteur - Vaccines Division

Jerome Contamine - Chief Financial Officer and Executive Vice President

Analysts

Richard Vosser - JP Morgan Chase & Co, Research Division

Michael Leuchten - Barclays Capital, Research Division

Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Philippe Lanone - Natixis Bleichroeder LLC, Research Division

Graham Parry - BofA Merrill Lynch, Research Division

Jo Walton - Crédit Suisse AG, Research Division

Mark Clark - Deutsche Bank AG, Research Division

Peter Verdult - Morgan Stanley, Research Division

Vincent Meunier - Exane BNP Paribas, Research Division

Presentation

Operator

Compare to:
Previous Statements by SNY
» Sanofi-Aventis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» sanofi-aventis' Management Host IR Thematic Call on Multiple Sclerosis (Transcript)
» sanofi-aventis' Management Presents at Credit Suisse Healthcare Conference (Transcript)

Welcome to the Sanofi 2012 Second Quarter Results Conference Call. I now hand over to Mr. Sébastien Martel and to Mr. Christoph Viehbacher. Sir, please go ahead. .

Sébastien Martel

Thank you. Hi, everyone, and welcome to our second quarter conference call. As always I must advise you that the information presented today in the call contains forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially. So I'd like to please ask you refer to our Form 20-F on file with the SEC and also our Document de Référence for a description of these risk factors.

So with me today on the call are Chris Viehbacher, our CEO; Hanspeter Spek, our President of Global Operations; Olivier Charmeil, Senior VP for Vaccines; and Jerome Contamine, our CFO.

1 2 3 4 Next › Last »